140 related articles for article (PubMed ID: 23541568)
1. Genetic deletion of the long isoform of the von Hippel-Lindau tumour suppressor gene product alters microtubule dynamics.
Frew IJ; Smole Z; Thoma CR; Krek W
Eur J Cancer; 2013 Jul; 49(10):2433-40. PubMed ID: 23541568
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice.
Wang J; Ma Y; Jiang H; Zhu H; Liu L; Sun B; Pan S; Krissansen GW; Sun X
J Hepatol; 2011 Aug; 55(2):359-68. PubMed ID: 21168458
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
4. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
5. Suppression of von Hippel-Lindau Protein in Fibroblasts Protects against Bleomycin-Induced Pulmonary Fibrosis.
Zhou Q; Chen T; Zhang W; Bozkanat M; Li Y; Xiao L; van Breemen RB; Christman JW; Sznajder JI; Zhou G
Am J Respir Cell Mol Biol; 2016 May; 54(5):728-39. PubMed ID: 26488390
[TBL] [Abstract][Full Text] [Related]
6. The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.
Lolkema MP; Mans DA; Snijckers CM; van Noort M; van Beest M; Voest EE; Giles RH
FEBS Lett; 2007 Oct; 581(24):4571-6. PubMed ID: 17825299
[TBL] [Abstract][Full Text] [Related]
7. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.
Hergovich A; Lisztwan J; Barry R; Ballschmieter P; Krek W
Nat Cell Biol; 2003 Jan; 5(1):64-70. PubMed ID: 12510195
[TBL] [Abstract][Full Text] [Related]
8. Multitasking by pVHL in tumour suppression.
Frew IJ; Krek W
Curr Opin Cell Biol; 2007 Dec; 19(6):685-90. PubMed ID: 18006292
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
10. VHL loss causes spindle misorientation and chromosome instability.
Thoma CR; Toso A; Gutbrodt KL; Reggi SP; Frew IJ; Schraml P; Hergovich A; Moch H; Meraldi P; Krek W
Nat Cell Biol; 2009 Aug; 11(8):994-1001. PubMed ID: 19620968
[TBL] [Abstract][Full Text] [Related]
11. The multifaceted von Hippel-Lindau tumour suppressor protein.
Robinson CM; Ohh M
FEBS Lett; 2014 Aug; 588(16):2704-11. PubMed ID: 24583008
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
13. A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein.
Bex C; Knauth K; Dambacher S; Buchberger A
Nucleic Acids Res; 2007; 35(21):e142. PubMed ID: 17986458
[TBL] [Abstract][Full Text] [Related]
14. Microtubular stability affects pVHL-mediated regulation of HIF-1alpha via the p38/MAPK pathway in hypoxic cardiomyocytes.
Teng M; Jiang XP; Zhang Q; Zhang JP; Zhang DX; Liang GP; Huang YS
PLoS One; 2012; 7(4):e35017. PubMed ID: 22506063
[TBL] [Abstract][Full Text] [Related]
15. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
Kuehn EW; Walz G; Benzing T
Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
17. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.
Rankin EB; Tomaszewski JE; Haase VH
Cancer Res; 2006 Mar; 66(5):2576-83. PubMed ID: 16510575
[TBL] [Abstract][Full Text] [Related]
18. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
Pantuck AJ; An J; Liu H; Rettig MB
Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
[TBL] [Abstract][Full Text] [Related]
19. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network.
Thoma CR; Frew IJ; Hoerner CR; Montani M; Moch H; Krek W
Nat Cell Biol; 2007 May; 9(5):588-95. PubMed ID: 17450132
[TBL] [Abstract][Full Text] [Related]
20. Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3.
Hergovich A; Lisztwan J; Thoma CR; Wirbelauer C; Barry RE; Krek W
Mol Cell Biol; 2006 Aug; 26(15):5784-96. PubMed ID: 16847331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
